Replies to post #254209 on Biotech Values

[Mufaso]

VKTX- A topline readout on ORAL VK2735 by end of q2 is aggressive. More likely q3 IMO.

Regarding VK2735 SubQ approval by end of 2027, I essentially agree and have indicated I my guess is early 2028 before.

More importantly, Viking will surprise many with an ability to produce VK2735 at scale very early on. I expect multi billion in revs in 2029 for VK2735.